Madhavan V. Pillai

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

J. Randolph Hecht, Madhavan V. Pillai, Russell Gollard et al. · Clinical Colorectal Cancer · 2010 · 73 citations

Medicine, Oncology, Pharmacology +14

The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status

Edith P. Mitchell, Bilal Piperdi, Mario E. Lacouture et al. · Clinical Colorectal Cancer · 2011 · 41 citations

Medicine, Oncology, Pharmacology +14

Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

Edith P. Mitchell, Mario E. Lacouture, Heather M. Shearer et al. · Journal of Clinical Oncology · 2009 · 23 citations

Pharmacy, Oncology, Pharmacotherapy +12

A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis

Edith P. Mitchell, Mario E. Lacouture, Heather M. Shearer et al. · Journal of Clinical Oncology · 2008 · 19 citations

Medicine, Oncology, Pharmacology +16